Moderna says FDA refuses to review its application for experimental flu shot

In this article

The Food and Drug Administration has refused to start a review of Moderna

’s application for its experimental flu shot, the company announced Tuesday, in another sign of the Trump administration’s influence on tightening vaccine regulations in the U.S.

The company’s stock fell roughly 7% in after-hours trading Tuesday.

Moderna said the move is inconsistent with previous feedback from the agency from before it submitted the application and started phase three trials on the shot, called mRNA-1010. The drugmaker said it has requested a meeting with the FDA to “understand the path forward.”